Shots:

• The P-III SURPASS-3 MRI sub-study evaluates the effects of tirzepatide (5/10/15mg- qw) vs titrated insulin degludec on LFC- VAT and ASAT in 296 patients with T2D for 52wks.
• The study met its 1EPs & 2EPs i.e.- (-8.09% from 15.67% vs -3.38% from 16.58%) absolute reduction from baseline in LFC for 10 & 15 mg dose; relative reduction (29.78% - 47.11% vs 11.17%) & patients achieved a 30% reduction in LFC from baseline (66.9%-81.4% vs 32.12%) for 3 doses- overall safety profile was similar to well-established GLP-1 receptor agonist
• The therapy showed a reduction in the volume of VAT & ASAT @52wks. Tirzepatide is a dual GIP & GLP-1 receptor agonist

Ref: PR Newswire | Image: Eli Lilly